Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study

BACKGROUND: Since 2016, the combination of sacubitril/valsartan, which combines an angiotensin receptor and neprilysin inhibitor (ARNI), has been recommended in the guidelines for the treatment of heart failure. The adoption of new drugs may be influenced by collaboration and exchange between physic...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Christine, Koetsenruijter, Jan, Forstner, Johanna, Peters-Klimm, Frank, Wensing, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401102/
https://www.ncbi.nlm.nih.gov/pubmed/34454547
http://dx.doi.org/10.1186/s13012-021-01150-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401102/
https://www.ncbi.nlm.nih.gov/pubmed/34454547
http://dx.doi.org/10.1186/s13012-021-01150-y

Ejemplares similares